Abingdon Health, a York-based diagnostics company leading the UK-Rapid Test Consortium (UK-RTC), and Medilink member, has received a CE mark for its COVID-19 rapid antibody test, which means that it is now approved for professional use in the UK and EU.
The rapid test for detection of lgG antibodies to the SARS-CoV-2 virus will be mass produced and tests will be rolled out from the end of August. The test can be administered by healthcare professionals, such as doctors, nurses, pharmacists and healthcare workers.
Following production of tens of thousands of tests across multiple production scale batches, the test has been shown to be 99.40% accurate. Testing was performed at the Ulster University and at the laboratories of Abingdon Health.
The test will be named the “AbC-19TM Rapid Test”. It uses a small drop of blood from a finger-prick, and shows results in 20 minutes, without the need to send a sample to a lab.
Chris Yates, CEO of Abingdon, said: “This UK designed, developed and manufactured high-quality rapid diagnostic test is a breakthrough for UK life sciences and a triumph of British business.
“It has been a company-wide effort at Abingdon Health to achieve this milestone in such a short space of time. Our research and development teams have been working two shifts a day, seven days a week, to develop the test. We have deployed nearly fifteen times the number of people that would be on a typical project to deliver this test as quickly as possible.”
To read more, please click here.